Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

A groundbreaking £1.65million gene therapy treatment offering hope for sickle cell disease patients has been approved for use ...

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

NHS England & Vertex reach deal for sickle cell gene therapy Casgevy, making it available at an undisclosed reduced price ...

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

A new innovative treatment for sickle cell disease will now be offered to patients in the NHS for the first time.A treatment, costing £1.65 provides hope for patients with severe sickle cell ...

Shares of Charter Communications, Inc. CHTR +5.52% Get Free Report rose during Friday's session after the company reported ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Columnist Mary Shaniqua explains how to be an ally to the sickle cell community, and why that kind of support is essential ...